This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Select Medical's (SEM) Concentra Submits Confidential IPO Filing
by Zacks Equity Research
The move from Select Medical's (SEM) Concentra highlights the recovery in the U.S. IPO market, especially for healthcare companies.
Evaluating Molina Healthcare's (MOH) Future View: Hold or Fold?
by Zacks Equity Research
Molina Healthcare's (MOH) top line is poised to gain from rising premium revenues and investment income.
Why Elevance (ELV) is a Smart Addition to Your Portfolio Now
by Zacks Equity Research
Elevance's (ELV) top line is poised to gain from rising product revenues, administrative fees and other revenues.
Elevance Health (ELV) Bolsters CarelonRx With Paragon Buyout
by Zacks Equity Research
The infusion services from Paragon Healthcare are expected to complement Elevance Health's (ELV) suite of pharmacy services.
An In-Depth Analysis of Encompass Health's (EHC) 2024 Outlook
by Zacks Equity Research
Growth in Medicare and Managed Care pricing, along with capacity additions of six de novos with 280 beds, will likely have an impact on Encompass Health's (EHC) 2024 bottom line.
The Joint (JYNT) Rises 30% as Q4 Earnings Beat on Higher Clinics
by Zacks Equity Research
The Joint (JYNT) expects 2024 system-wide sales to be within $530-$545 million.
Ensign Group (ENSG) Up 30.8% in 6 Months: More Growth Ahead?
by Zacks Equity Research
Ensign Group's (ENSG) growing strength in its Skilled Services business is a major upside.
HCA Healthcare (HCA) Rises 24.8% in a Year: More Room to Run?
by Zacks Equity Research
HCA Healthcare's (HCA) growing equivalent admissions are supporting performance.
After Plunging -24.47% in 4 Weeks, Here's Why the Trend Might Reverse for Health Catalyst (HCAT)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Health Catalyst (HCAT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Compared to Estimates, Health Catalyst (HCAT) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Health Catalyst (HCAT) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Health Catalyst (HCAT) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Health Catalyst (HCAT) delivered earnings and revenue surprises of 300% and 1.92%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Health Catalyst (HCAT) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Health Catalyst (HCAT), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.
Insulet (PODD) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Insulet (PODD) is expected to have benefited from the ongoing rollout of Omnipod 5 in several international markets in the fourth quarter.
Ecolab (ECL) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Ecolab's (ECL) fourth-quarter results are likely to be driven by its Food & Beverage, Water business along with the Institutional segment.
DaVita (DVA) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Improvement in revenue per treatment and cost-saving initiatives are likely to have boosted DaVita's (DVA) top line in the fourth quarter.
Catalent (CTLT) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Catalent's (CTLT) fiscal second-quarter results are likely to be driven by its non-COVID non-Sarepta Biologics business.
Bio-Rad Laboratories (BIO) to Post Q4 Earnings: What Awaits?
by Zacks Equity Research
Ongoing weakness in the biopharma end markets, impacting the sales of Life Science tools and bioprocessing products, are likely to have impeded Bio-Rad's (BIO) Q4 revenues.
Charles River (CRL) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
The service business within Charles River (CRL) RMS is expected to have witnessed growth in the fourth quarter, banking on small molecule revenue increase across several geographic regions.
Wall Street Analysts Believe Health Catalyst (HCAT) Could Rally 28.97%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 29% upside potential for Health Catalyst (HCAT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Compared to Estimates, Health Catalyst (HCAT) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Health Catalyst (HCAT) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
All You Need to Know About Health Catalyst (HCAT) Rating Upgrade to Strong Buy
by Zacks Equity Research
Health Catalyst (HCAT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Health Catalyst (HCAT) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Health Catalyst (HCAT) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Health Catalyst (HCAT) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Health Catalyst (HCAT) delivered earnings and revenue surprises of 266.67% and 0.75%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Enovis (ENOV) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Enovis (ENOV) delivered earnings and revenue surprises of 15.09% and 2.23%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Compared to Estimates, Health Catalyst (HCAT) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Health Catalyst (HCAT) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.